Palvella Therapeutics Inc stock is traded at $156.85, with a volume of 269,776. It is down -3.35% in the last 24 hours and up +18.68% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Previous Close:
$162.28
Open:
$166.73
24h Volume:
269,776
Relative Volume:
0.97
Market Cap:
$2.26B
Revenue:
$1.30M
Net Income/Loss:
-$49.30M
P/E Ratio:
-
EPS:
-$4.17
Net Cash Flow:
-$29.10M
1W Performance:
+3.48%
1M Performance:
+18.68%
6M Performance:
+21.15%
1Y Performance:
+107.06%
1-Day Range:
$153.40$166.73
1-Week Range:
$141.98$166.73
52-Week Range:
$72.23$166.73
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(484) 253-1461Address
353 W. LANCASTER AVENUE, WAYNE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS